Few reports of long-term response with pazopanib in advanced renal-cell carcinoma (aRCC) exist, and associated factors are unknown. A total of 153 first-line pazopanib-treated patients with aRCC were evaluated for long-term response (progression-free survival ‡ 18 months) in a real-world setting. An Eastern Cooperative Oncology Group performance status of 0 and nephrectomy history were significant predictors of long-term response in this patient population. Background: Pazopanib is among the current standards of care for first-line treatment of patients with unresectable advanced renal-cell carcinoma (aRCC) or metastatic renal-cell carcinoma. This real-world study aimed to characterize those with long-term response to pazopanib in the treatment of aRCC in a community oncology setting, and to identify predictors of long-term response. Patients and Methods: aRCC patients treated with first-line pazopanib were classified as having long-term or nonelong-term response (progression-free survival [PFS] of 18 or < 18 months, respectively). Baseline patient demographics and clinical characteristics were evaluated and compared between the 2 groups. Differences in PFS and overall survival were also evaluated. Results: A total of 153 eligible patients were identified, of which 33 (21.6%) and 120 (78.4%) patients were identified as having disease with long-term and non elong-term response, respectively. The median PFS for those with long-term response was 27.2 months (95% confidence interval [CI], 23.0-35.2) versus 6.9 months (95% CI, 5.0-8.6) for those with nonelong-term response. Median overall survival was not reached (NR) for those with long-term response (95% CI, NR to 39.1) compared to 15.3 months (95% CI, 12.3-21.6) for those with nonelong-term response. Baseline Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 (vs. ECOG PS of 1 and 2) and history of nephrectomy were identified as significant predictors of long-term response to pazopanib. Conclusion: In aRCC patients treated with first-line pazopanib, 22% had a long-term response. Significant predictors of long-term response included an ECOG PS of 0 and a history of nephrectomy.
Introduction
Kidney cancer is one of the most frequently diagnosed cancers in men and women in the United States, with the most common type being renal-cell carcinoma (RCC). 1 The discovery of genetic aberrations in the von Hippel-Lindau gene in patients with RCC led to the development of agents that target the related pathway, namely vascular endothelial growth factor (VEGF), which has vastly improved outcomes for patients with advanced RCC (aRCC).
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The VEGF receptor tyrosine kinase inhibitors (TKIs) sunitinib and pazopanib are the standard of care for the first-line treatment of patients with unresectable advanced or metastatic RCC (mRCC). [6] [7] [8] First-line pazopanib significantly prolonged progression-free survival (PFS) relative to placebo in the pivotal phase 3 trial, and demonstrated noninferior efficacy to sunitinib in the head-to-head phase 3 COMPARZ trial. 5, 9 Despite the proven clinical benefit, few reports of long-term response with pazopanib in aRCC exist, 10- factors associated with a long-term response to pazopanib are unknown. The objective of this study was to characterize those with longterm response to pazopanib in a real-world setting for the treatment of aRCC, and to identify predictors of long-term response.
Methods

Study Design and Patients
aRCC patients treated with first-line pazopanib were identified using the US Oncology Network's iKnowMed (iKM) electronic health record (EHR) database, supplemented with chart review. The iKM database is an integrated web-based database of the oncologyspecific EHR system maintained by McKesson Specialty Health and was used to provide patient-level demographic and clinical data. The iKM database was linked to the Social Security Death Index to supplement the vital status (death of patients). The charts of patients identified through the iKM database were reviewed to provide supplemental clinical data, including treatment, disease progression, and adverse events.
Eligible patients were 18 years old at first diagnosis of aRCC and had a documented primary diagnosis of stage III or IV RCC in the iKM database, or who were diagnosed with disease at an early stage but developed metastatic disease. Patients must have initiated first-line pazopanib therapy between November 1, 2009, and August 31, 2012, and had 2 visits during the follow-up period (through October 31, 2014). Patients were excluded if they were enrolled in a clinical trial, diagnosed with and treated for other primary cancers during the study period, or diagnosed with RCC but initiated a first-line treatment other than pazopanib. To limit selection bias, patients treated with first-line pazopanib were paired with first-line sunitinib patients using propensity score matching. Although there is no accepted definition of long-term response in patients with aRCC, previous publications describing long-term response to sunitinib have utilized the 18-month cutoff for PFS. [13] [14] [15] Therefore, patients in the pazopanib cohort were classified as having disease with long-term response (PFS 18 months) or with nonelong-term response (PFS < 18 months).
Statistical Analysis
Baseline patient demographics and clinical characteristics were compared between patients with long-term response and those with nonelong-term response by 2-sided chi-square tests; P < .05 was considered statistically significant. Kaplan-Meier survival analysis was used to calculate median PFS and overall survival. Patients without PFS or overall survival events were censored at the last visit date or at the end of study follow-up, whichever occurred first. A multivariate logistic regression analysis, which was based on statistical significance in the univariate analysis as well as clinical relevance of some factors, was performed to identify significant predictors of long-term response to pazopanib using baseline demographic and clinical characteristics. Factors included in the analysis were age, sex, number of comorbidities (cardiovascular disease, renal/urinary, pulmonary, or infection comorbidities in the 12 months before the index date), Eastern Cooperative Oncology Group (ECOG) performance status (PS) at baseline, prior nephrectomy, history of chronic renal failure syndrome, and metastatic status. These factors were selected on the basis of the descriptive analysis of long-term response. Other analytic factors (hemoglobin, lactate dehydrogenase, calcium, neutrophils, platelets) were excluded from the analysis. Heng score is a synthesized index of these factors (in addition to other factors). It is validated and may better reflect the risk of RCC patients. Adding these individual factors may cause autocorrelation in the regression model, and they therefore were excluded.
Results
Patient Characteristics
In total, 1304 aRCC patients treated with first-line therapy were identified in the iKM database, of whom 1082 received first-line TKIs. Of the 216 (20.0%) pazopanib and 866 (80.0%) sunitinib patients, 832 patients overall (174 with pazopanib and 658 with sunitinib) were eligible for propensity score matching, which resulted in a total of 153 propensity scoreematched patients in each of the pazopanib and sunitinib cohorts. Among the 153 patients treated with first-line pazopanib, 33 (21.6%) and 120 (78.4%) were identified as having disease with long-term response (PFS 18 months) and disease with nonelong-term response (PFS < 18 months), respectively. Demographic and clinical characteristics between those with long-term response and those with nonelongterm response are shown in Table 1 . Those with long-term response were significantly more likely to have a lower ECOG PS at baseline and a history of nephrectomy compared to those with nonelongterm response. Although not statistically significant, the trend suggested that bone and brain metastases were more frequent in the nonelong-term response cohort. Other factors between the 2 groups were not statistically significantly different.
Survival Analysis
Median PFS was 27.2 months (95% confidence interval [CI], 23.0-35.2) in those with long-term response and 6.9 months (95% CI, 5.0-8.6) in those with nonelong-term response (Figure 1) . At the time of analysis, 26 (79%) of those with long-term response and 54 (45%) of those with nonelong-term response had been censored for overall survival. Median overall survival was not reached (NR) for those with long-term response (95% CI, NR to 39.1) and was 15.3 months (95% CI, 12.3-21.6) for those with nonelong-term response.
Predictors of Long-Term Response to Pazopanib
The multivariate logistic regression analysis, which controlled for demographic and clinical characteristics, revealed that a baseline ECOG PS of 0 (vs. ECOG PS of 1 and 2) and history of nephrectomy were significant predictors of long-term response to pazopanib ( Table 2) .
Discussion
This retrospective analysis of EHRs from a community oncology clinic network demonstrated that select aRCC patients experienced a long-term response (PFS 18 months) with pazopanib, with a median PFS of 27.2 months. Factors that were significantly associated with long-term response in the real-world setting included favorable ECOG PS at the time of treatment initiation and history of nephrectomy. The identification of factors predictive of clinical benefit with pazopanib will inform clinicians about which patients
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Long-Term Response With Pazopanib may benefit most from this therapy. Indeed, pazopanib and sunitinib both carry the highest level of evidence in treatment guideline recommendations for the first-line treatment of patients with unresectable aRCC or mRCC; however, no guidance is given about which treatment options should be provided to various patients. [6] [7] [8] Similar to this study, efforts to identify those with long-term response to sunitinib have also been made. In one retrospective pooled analysis of 186 patients treated with sunitinib monotherapy or combination therapy, 18% experienced PFS 18 months, 15 which is similar to the proportion of those with long-term response in the current study of pazopanib (22%). Clinical factors significantly associated with long-term sunitinib response included bone metastasis, lung metastasis, and favorable Memorial Sloan Kettering Cancer Center risk group. The sunitinib study did not include ECOG PS and 
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nephrectomy history in their logistic regression analysis; these were the clinical factors significantly associated with pazopanib those with long-term response in the current study. Because nephrectomy is the standard of care for treating localized RCC, [6] [7] [8] and because cytoreductive nephrectomy before VEGF-targeted therapy has previously been demonstrated to confer a significant survival benefit in mRCC patients, 16 it is not surprising that prior nephrectomy was a significant predictor of long-term response with pazopanib. In addition, history of nephrectomy as a predictive factor may imply that patients who were diagnosed with RCC at an early stage of the disease have more favorable treatment outcomes, and it is likely that nephrectomy history is more prognostic than predictive of treatment benefit. ECOG PS may also have more prognostic than predictive impact, as Karnofsky PS has previously been identified as an independent prognostic factor for survival and is included in both the Memorial Sloan Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium prognostic models. 17, 18 The current study also found that those with disease with nonelong-term response to pazopanib more frequently had bone metastases, and although this finding was not significant in the multivariate analysis, the result is consistent with growing awareness that bone metastases are an adverse prognostic factor in patients with mRCC. 19 Although this study provides the first evidence of clinical factors associated with long-term response with pazopanib, these results should be interpreted with caution because of the retrospective nature and the small sample size of this multi-institution study. Large prospective studies are required to comprehensively analyze clinical factors that may be associated with long-term response to TKIs, such as pazopanib.
Conclusion
In this US Oncology Network iKM EHR database study of 153 eligible patients treated with first-line pazopanib in a real-world setting, 22% had a long-term response (PFS 18 months); significant predictors of long-term response were a favorable ECOG PS (0) and history of nephrectomy. Larger prospective studies are required to confirm these predictors, with the aim of aiding treatment selection.
Clinical Practice Points
Few reports of long-term response with pazopanib in aRCC exist, and factors associated with a long-term response to pazopanib are unknown. This real-world retrospective analysis demonstrated that select aRCC patients achieved a long-term response (PFS 18 months) with pazopanib, and that long-term response was significantly associated with favorable ECOG PS at the time of treatment initiation and history of nephrectomy. By identifying factors predictive of clinical benefit with pazopanib, clinicians will have greater insight about which patients may benefit most from this therapy.
